Literature DB >> 25916517

SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization.

Josephine H Li1, Sunil Suchindran, Svati H Shah, William E Kraus, Geoffrey S Ginsburg, Deepak Voora.   

Abstract

AIM: SLCO1B1 variants are associated with intermediate outcomes that may increase risk of death/myocardial infarction (MI) in statin-treated patients. PATIENTS &
METHODS: In high-risk Caucasians undergoing cardiac catheterization, we tested the association between rs4149056/625T>C and rs2306283/492A>G with low-density lipoprotein cholesterol (LDL-c) over 3 years (n = 1402) and death/MI over 6 years (n = 2994), accounting for statin use or type during follow-up.
RESULTS: Carriers of the rs4149056 C allele had 6.2 ± 1.7 mg/dl higher LDL-c per C allele (p < 0.001) but were not at higher risk for death/MI (p = 0.9). We found no associations between rs2306283 and LDL-c or death/MI (p > 0.6).
CONCLUSION: Functional SLCO1B1 variants are not associated with death/MI in patients commonly treated with statins, despite higher LDL-c in carriers of the rs4149056 C allele.

Entities:  

Keywords:  SLCO1B1; cardiovascular events; low-density lipoprotein cholesterol; myocardial infarction; pharmacogenetics; rs2306283; rs4149056; statin

Mesh:

Substances:

Year:  2015        PMID: 25916517      PMCID: PMC4719145          DOI: 10.2217/pgs.15.2

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  44 in total

Review 1.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

3.  Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations.

Authors:  Michael H Davidson; Kevin C Maki; Thomas A Pearson; Richard C Pasternak; Prakash C Deedwania; James M McKenney; Gregg C Fonarow; David J Maron; Benjamin J Ansell; Luther T Clark; Christie M Ballantyne
Journal:  Am J Cardiol       Date:  2005-08-15       Impact factor: 2.778

4.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins.

Authors:  C L Shear; F A Franklin; S Stinnett; D P Hurley; R H Bradford; A N Chremos; D T Nash; A Langendorfer
Journal:  Circulation       Date:  1992-04       Impact factor: 29.690

5.  Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia.

Authors:  Elizabeth S Parris; David B Lawrence; Lisa A Mohn; Laura B Long
Journal:  Diabetes Care       Date:  2005-03       Impact factor: 19.112

6.  Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.

Authors:  Yoshio Kameyama; Keiko Yamashita; Kaoru Kobayashi; Masakiyo Hosokawa; Kan Chiba
Journal:  Pharmacogenet Genomics       Date:  2005-07       Impact factor: 2.089

Review 7.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

8.  Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]).

Authors:  Pernette R W de Sauvage Nolting; Rudolf J A Buirma; Barbara A Hutten; John J P Kastelein
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

9.  Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgery.

Authors:  L R Smith; F E Harrell; J S Rankin; R M Califf; D B Pryor; L H Muhlbaier; K L Lee; D B Mark; R H Jones; H N Oldham
Journal:  Circulation       Date:  1991-11       Impact factor: 29.690

10.  Adherence with statin therapy in elderly patients with and without acute coronary syndromes.

Authors:  Cynthia A Jackevicius; Muhammad Mamdani; Jack V Tu
Journal:  JAMA       Date:  2002 Jul 24-31       Impact factor: 56.272

View more
  7 in total

1.  Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport.

Authors:  Jonathan B Wagner; Melissa Ruggiero; J Steven Leeder; Bruno Hagenbuch
Journal:  Drug Metab Dispos       Date:  2020-09-05       Impact factor: 3.922

2.  Polypharmacy: a healthcare conundrum with a pharmacogenetic solution.

Authors:  Cierra N Sharp; Mark W Linder; Roland Valdes
Journal:  Crit Rev Clin Lab Sci       Date:  2019-11-02       Impact factor: 6.250

3.  The Association between Single Nucleotide Polymorphisms, including miR-499a Genetic Variants, and Dyslipidemia in Subjects Treated with Pharmacological or Phytochemical Lipid-Lowering Agents.

Authors:  Angelica Giuliani; Alberto Montesanto; Giulia Matacchione; Laura Graciotti; Deborah Ramini; Olga Protic; Roberta Galeazzi; Roberto Antonicelli; Elena Tortato; Anna Rita Bonfigli; Jacopo Sabbatinelli; Fabiola Olivieri
Journal:  Int J Mol Sci       Date:  2022-05-17       Impact factor: 6.208

4.  Pharmacogenetics in Cardiovascular Medicine.

Authors:  Sony Tuteja; Nita Limdi
Journal:  Curr Genet Med Rep       Date:  2016-06-16

5.  LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.

Authors:  Wei-Qi Wei; Xiaohui Li; Qiping Feng; Michiaki Kubo; Iftikhar J Kullo; Peggy L Peissig; Elizabeth W Karlson; Gail P Jarvik; Ming Ta Michael Lee; Ning Shang; Eric A Larson; Todd Edwards; Christian M Shaffer; Jonathan D Mosley; Shiro Maeda; Momoko Horikoshi; Marylyn Ritchie; Marc S Williams; Eric B Larson; David R Crosslin; Sarah T Bland; Jennifer A Pacheco; Laura J Rasmussen-Torvik; David Cronkite; George Hripcsak; Nancy J Cox; Russell A Wilke; C Michael Stein; Jerome I Rotter; Yukihide Momozawa; Dan M Roden; Ronald M Krauss; Joshua C Denny
Journal:  Circulation       Date:  2018-10-23       Impact factor: 29.690

6.  Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia.

Authors:  Jonathan B Wagner; Susan Abdel-Rahman; Andrea Gaedigk; Roger Gaedigk; Geetha Raghuveer; Vincent S Staggs; Leon Van Haandel; J Steven Leeder
Journal:  Clin Transl Sci       Date:  2020-03-09       Impact factor: 4.689

7.  The Pharmacogenetics of Statin Therapy on Clinical Events: No Evidence that Genetic Variation Affects Statin Response on Myocardial Infarction.

Authors:  Stella Trompet; Iris Postmus; Helen R Warren; Raymond Noordam; Roelof A J Smit; Elizabeth Theusch; Xiaohui Li; Benoit Arsenault; Daniel I Chasman; Graham A Hitman; Patricia B Munroe; Jerome I Rotter; Bruce M Psaty; Mark J Caulfield; Ron M Krauss; Adrienne L Cupples; Wouter J Jukema
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.